

ADONIS - Electronic Journal Services

Requested by

Adonis

Article title Erinacin, an antihemorrhagic factor from the European hedgehog, *Erinaceus europaeus*

Article identifier 0041010197002178

Authors Mebs_D Omori-Satoh_T Yamakawa_Y Nagaoka_Y

Journal title Toxicon

ISSN 0041-0101

Publisher Pergamon

Year of publication 1996

Volume 34

Issue 11-12

Supplement 0

Page range 1313-1316

Number of pages 4

User name Adonis

Cost centre Development

PCC \$20.00

Date and time Tuesday, June 24, 2003 10:43:21 AM

Copyright © 1991-1999 ADONIS and/or licensors.

The use of this system and its contents is restricted to the terms and conditions laid down in the Journal Delivery and User Agreement. Whilst the information contained on each CD-ROM has been obtained from sources believed to be reliable, no liability shall attach to ADONIS or the publisher in respect of any of its contents or in respect of any use of the system.



ERINACIN, AN ANTIHAEMORRHAGIC FACTOR FROM THE EUROPEAN HEDGEHOG, *ERINACEUS EUROPAEUS*

D. MEBS,¹ T. OMORI-SATOH,² Y. YAMAKAWA² and Y. NAGAOKA²

¹Zentrum der Rechtsmedizin, University of Frankfurt, Kennedyallee 104, D-60596, Frankfurt, Germany; and ²National Institute of Health, Toyama 1-23-1, Shinjuku, F162, Tokyo, Japan

(Received 14 September 1995; accepted 23 October 1995)

D. Mebs, T. Omori-Satoh, Y. Yamakawa and Y. Nagaoka. Erinacin, an antihemorrhagic factor from the European hedgehog, *Erinaceus europaeus*. *Toxicol* 34, 1313–1316, 1996.—An antihemorrhagic factor named erinacin was purified from the skeletal muscle extract of the European hedgehog, *Erinaceus europaeus*, by ammonium sulfate precipitation followed by various steps of ion-exchange (DEAE-cellulose), absorption chromatography (hydroxylapatite), and gel filtration (cellofine gel). A 625-fold purification was achieved with an overall yield of 19% antihemorrhagic activity. The protein effectively inhibited the activity of *Bothrops jararaca* venom hemorrhagin and did not inhibit the enzymatic activity of trypsin and chymotrypsin. Erinacin is a large molecule (about 1,000,000 mol. wt). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis revealed the presence of two subunits: one with an apparent mol. wt of 35,000 forming a larger subunit (350,000) by cross-linking with disulfide bridges, and a second with a mol. wt of 39,000 without disulfides. Dissociation of erinacin into its subunits resulted in complete loss of its antihemorrhagic activity. Copyright © 1996 Elsevier Science Ltd

INTRODUCTION

Proteins inhibiting the activity of snake venom hemorrhagins have been detected in the blood of venomous and non-venomous snakes, as well as various mammals (Domont *et al.*, 1991). From the plasma of the European hedgehog, which occasionally feeds on vipers (*Vipera* sp.) and which seems to be resistant to their venoms, an antihemorrhagic factor also exhibiting proteinase inhibitor activity has been isolated and characterized to be a β -macroglobulin with a mol. wt of 700,000 (De Wit and Weström, 1987a, b). Similar activity inhibiting hemorrhagins in several venoms from snakes such as *Bitis* sp., *Bothrops asper* and *Bothrops jararaca*. *Vipera berus* and *Vipera latastei* has been found in skeletal muscle extracts of the hedgehog (Omori-Satoh *et al.*, 1994).

This report describes the purification of this antihemorrhagic factor, named erinacin, and its subunit composition.

MATERIALS AND METHODS

Hedgehogs (*Erinaceus europaeus*) which were found dead on roads (killed 5-6 hr before) around Frankfurt (Germany) were used. Muscle samples were excised, homogenized in physiological saline using a blender and centrifuged, and the supernatant was lyophilized. The minimum haemorrhagic dose (MHD) producing a haemorrhagic spot of 10 mm diameter in depilated rabbit skin was assayed according to the method of Kondo *et al.* (1960) using crude venom from *B. jararaca* (MHD 0.082 µg). A dose of 25 MHD was incubated with varying amounts of muscle extracts or its fractions in 0.5 ml (0.01 M phosphate-buffered saline, pH 7.0) at room temperature for 1 hr, and 0.2 ml of the mixture (10 MHD of venom) was tested; the antihaemorrhagic dose was defined as the amount of material (mg) inhibiting 10 MHD of the venom.

RESULTS AND DISCUSSION

Purification of the antihaemorrhagic factor erinacin

The lyophilized muscle extract was dissolved in 0.05 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, and centrifuged, and 50 ml of saturated ammonium sulfate solution was added to the supernatant (100 ml). The precipitate, dissolved in 0.05 M Tris-HCl buffer, pH 8.5, and dialysed against the same buffer, was applied to a DEAE-cellulofine column eluted with a linear gradient of NaCl (0.3 M). The fractions exhibiting antihaemorrhagic activity were further separated on a hydroxylapatite column eluted with a linear gradient of phosphate buffer (0.01-0.3 M, pH 7.0). Final purification was achieved by gel filtration on a cellulose GCL-2000 superfine column (Fig. 1). Erinacin was obtained with an overall yield of 19% of antihaemorrhagic activity, purified 625-fold. The preparation was homogeneous in polyacrylamide gel electrophoresis (PAGE) and gel high-performance liquid chromatography (HPLC). The molecule is stable, and no loss of activity was observed when stored in solution at 4°C, which is in contrast to observations on the plasma antihaemorrhagic factor described by De Wit and Weström (1987b).

Molecular weight and subunit composition of erinacin

In gel filtration erinacin behaved as a large molecule eluting slightly faster than immunoglobulin M (900,000 mol. wt), suggesting a mol. wt of about 1,000,000. In sodium




Fig. 1. Purification of the antihaemorrhagic factor erinacin from skeletal muscle extract of the European hedgehog, *Erinaceus europaeus*.

dodecyl sulfate (SDS)-PAGE under reducing conditions (mercaptoethanol) two bands corresponding to 35,000 and 39,000 mol. wt, respectively, occurred, indicating that erinacin consists of two polypeptide subunits.

After exposure to 6 M guanidine-HCl the protein dissociated into two components separated by gel HPLC: S1 and S2, in a ratio of 1:2 (protein amount). This treatment caused complete loss of antihemorrhagic activity, which was not restored by combining the fractions. Whereas the mol. wt of S2 was calculated to be about 350,000, that of S1 was estimated to be 39,000. By reducing the disulfide bonds in S2, components exhibiting a mol. wt of 35,000 were obtained in SDS-PAGE.

From these data it is concluded that erinacin is a complex of various subunits: two identical molecules (S2) consisting of ten subunits (each of mol. wt 35,000), which are cross-linked by disulfide bridges, and ten smaller subunits (S1, mol. wt 39,000). Altogether, S1 (390,000) and $2 \times$ S2 (350,000) amount to a total mol. wt of 1,090,000. The antihemorrhagic factor from the hedgehog plasma, characterized as β -macroglobulin, had also been found to have a mol. wt of 700,000 and was supposed to consist of two types of subunits with mol. wts of 34,000 and 39,000 (De Wit and Weström, 1987b).

Inhibition of proteinase activity

When erinacin was preincubated with TPCK-trypsin or chymotrypsin in a molar ratio of 1:1, inhibition of esterolytic activity of both enzymes was observed (TAME and BTEE as substrates).

CONCLUSION

Erinacin is an exceptionally large molecule with a complex subunit composition. It is not related to other antihemorrhagic factors isolated so far, such as from snake serum (*Trimeresurus flavoviridis*), which belongs to the cystatins (Yamakawa and Omori-Satoh, 1992), from opossum serum (*Didelphis virginiana*), a protein similar to human α 1B-glycoprotein (Catanese and Kress, 1993), or from mongoose serum (*Herpestes edwardsii*), which exhibits sequence homology to oprin (Qi *et al.*, 1995). However, it may be related to the antihemorrhagic factor found in the plasma of the hedgehog. Studies are in progress to elucidate the structural basis of the antihemorrhagic activity of this peculiar molecule.

REFERENCES

- Catanese, J. J. and Kress, L. F. (1993) Opossum serum α -proteinase inhibitor: purification, linear sequence, and resistance to inactivation by rattlesnake venom metalloproteinases. *Biochemistry* **32**, 509-515.
- De Wit, C. A. and Weström, B. R. (1987a) Venom resistance in the hedgehog, *Erinaceus europaeus*: purification and identification of macroglobulin inhibitors as plasma antihemorrhagic factor. *Toxicon* **25**, 315-323.
- De Wit, C. A. and Weström, B. R. (1987b) Purification and characterization of α -, α - β - and β -macroglobulin inhibitors in the hedgehog, *Erinaceus europaeus*: β -macroglobulin identified as the plasma antihemorrhagic factor. *Toxicon* **25**, 1209-1219.
- Domont, G. B., Perales, J. and Moussatché, H. (1991) Natural anti-snake venom proteins. *Toxicon* **29**, 1183-1194.
- Kondo, H., Kondo, S., Ikezawa, H., Murata, R. and Ohsaka, A. (1960) Studies on the quantitative method for determination of hemorrhagic activity of Habu snake venom. *Jpn. J. med. Sci. Biol.* **13**, 43-51.
- Omori-Satoh, T., Nagaoka, Y. and Mebs, D. (1994) Muscle extract of hedgehog, *Erinaceus europaeus*, inhibits hemorrhagic activity of snake venoms. *Toxicon* **32**, 1279-1281.

- Qi, Z.-Q., Yonaha, K., Tomihara, Y. and Toyama, S. (1995) Isolation of peptides homologous to domains of human α 1B-glycoprotein from a mongoose antihemorrhagic factor. *Toxicon* **33**, 241-245.
- Yamakawa, Y. and Omori-Sato, T. (1992) Primary structure of the antihemorrhagic factor in serum of the Japanese Habu: a snake venom metalloproteinase inhibitor with a double-headed cystatin domain. *J. Biochem.* **112**, 583-589.